推薦產品
等級
certified reference material
品質等級
形狀
liquid
特點
Snap-N-Spike®/Snap-N-Shoot®
包裝
ampule of 1 mL
製造商/商標名
Cerilliant®
濃度
1.0 mg/mL in methanol
技術
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
mp
128-131 °C (lit.)
應用
clinical testing
clinical testing
形式
single component solution
儲存溫度
−20°C
SMILES 字串
NC(=O)c1cccnc1
InChI
1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)
InChI 密鑰
DFPAKSUCGFBDDF-UHFFFAOYSA-N
尋找類似的產品? 前往 產品比較指南
一般說明
烟酰胺也称为烟碱酰胺或尼古丁酰胺。它是植物和动物食物中维生素B3的水溶性形式,并主要用作膳食补充剂。
應用
生化/生理作用
烟酰胺是维生素B3的酰胺衍生物,是PARP抑制剂
法律資訊
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
相關產品
產品號碼
描述
訂價
訊號詞
Danger
危險分類
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
標靶器官
Eyes
儲存類別代碼
3 - Flammable liquids
水污染物質分類(WGK)
WGK 2
閃點(°F)
49.5 °F - closed cup
閃點(°C)
9.7 °C - closed cup
客戶也查看了
Simultaneous determination of riboflavin, pyridoxine, nicotinamide, caffeine and taurine in energy drinks by planar chromatography-multiple detection with confirmation by electrospray ionization mass spectrometry
Aranda M and Morlock G
Journal of Chromatography A, 1131(1-2), 253-260 (2006)
Simultaneous determination and classification of riboflavin, thiamine, nicotinamide and pyridoxine in pharmaceutical formulations, by UV-visible spectrophotometry and multivariate analysis
Lopez-de-Alba LP, et al.
Journal of the Brazilian Chemical Society, 17(4), 715-722 (2006)
Case of sorafenib-induced thyroid storm.
Sigurdis Haraldsdottir et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(16), e262-e264 (2013-04-24)
Takeshi Natori et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(5), 635-637 (2013-07-19)
Sorafenib is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis signal transduction pathways. Two global phase III trials showed that sorafenib prolonged the survival of patients with advanced hepatocellular carcinoma (HCC). Based on the positive results of these
Noriaki Kitada et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(4), 479-482 (2013-07-16)
The current status of treatment with sorafenib, and factors affecting the duration of treatment in patients started on sorafenib for hepatocellular carcinoma from July 2009 until April 2011 in the Department of Gastroenterology at Kobe City Medical Center General Hospital
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務